How has been the historical performance of Biogen Pharma?

Answer:The historical performance of Biogen Pharma shows significant fluctuations in its financial metrics over the years, with a notable decline in net sales and profitability in recent periods.

Breakdown:
Biogen Pharma's net sales have been inconsistent, with figures of 2.47 Cr in Mar'22, dropping to 0.00 Cr in Mar'23, Mar'24, and Mar'25. Other operating income has also varied, peaking at 2.38 Cr in Mar'24 before falling to 0.84 Cr in Mar'25. Total operating income followed a similar trend, reaching 2.16 Cr in Mar'22 but declining to 0.84 Cr by Mar'25. The company's total expenditure, excluding depreciation, was highest at 2.18 Cr in Mar'22 and decreased to 1.13 Cr in Mar'25. Operating profit (PBDIT) showed a positive trend in Mar'24 at 1.93 Cr but turned negative to -0.29 Cr in Mar'25. Profit before tax mirrored this decline, moving from a profit of 1.93 Cr in Mar'24 to a loss of 0.29 Cr in Mar'25. Consequently, profit after tax also fell from 1.93 Cr to -0.29 Cr in the same period. The company's total assets increased from 54.83 Cr in Mar'23 to 56.82 Cr in Mar'24, but the net profit has remained negative in the latest year. Cash flow from operating activities remained stable at 1.00 Cr in Mar'24 and Mar'23, while cash flow from investing activities turned negative, indicating increased investments or expenditures. Overall, Biogen Pharma has faced challenges in maintaining revenue and profitability, particularly in the most recent fiscal years.